A
7.97
-0.36 (-4.32%)
| Previous Close | 8.33 |
| Open | 8.21 |
| Volume | 97,356 |
| Avg. Volume (3M) | 125,990 |
| Market Cap | 2,514,040,832 |
| Price / Earnings (Forward) | 43.67 |
| Price / Sales | 4.34 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 |
| Profit Margin | -47.13% |
| Operating Margin (TTM) | 9.32% |
| Diluted EPS (TTM) | -0.870 |
| Quarterly Revenue Growth (YOY) | 177.40% |
| Quarterly Earnings Growth (YOY) | -65.50% |
| Current Ratio (MRQ) | 2.35 |
| Operating Cash Flow (TTM) | -236.84 M |
| Levered Free Cash Flow (TTM) | -350.88 M |
| Return on Assets (TTM) | 4.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Alvotech | Mixed | Bearish |
AIStockmoo Score
1.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | 1.38 |
|
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 63.80% |
| % Held by Institutions | 6.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Littlejohn & Co Llc | 31 Dec 2024 | 1,318,534 |
| Pointstate Capital Lp | 31 Dec 2024 | 1,241,379 |
| Lodbrok Capital Llp | 31 Dec 2024 | 181,587 |
| Oaktree Fund Advisors, Llc | 31 Dec 2024 | 116,294 |
| 52 Weeks Range | ||
| Median | 18.00 (125.85%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 14 Feb 2025 | 18.00 (125.85%) | Buy | 12.99 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |